Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24847164 | 0.91 | DPP4 (0.33) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL30180168 | 0.91 | DPP4 (0.33) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL30768491 | 0.87 | GAA (0.33) | — | |
| SCHEMBL30768488 | 0.86 | DPP4 (0.36) | DPP4 | |
| SCHEMBL21876617 | 0.81 | LPL (0.39) | — | |
| SCHEMBL28963195 | 0.79 | — | — | |
| SCHEMBL26447710 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL24681526 | 0.79 | MAPT (0.40) | — | |
| SCHEMBL31289261 | 0.78 | CCR1 (0.41) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL19358414 | 0.78 | KDM4E (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-03-27 | — | — | US | disclosed |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240076281-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| EP-4317146-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-116917280-A | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3689868-B1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| CN-111454248-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | 阿尔维纳斯运营股份有限公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3548483-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2018-06-07 | — | — | US | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240076281-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | DPP4 4653/4885DPP8 3900/4885DPP9 4621/4885 |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | DPP4 4653/4885DPP8 3900/4885DPP9 4621/4885 |
| US-20250099596-A1 | TETRAHYDRONAPHTHALENE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | CYP51A1, CYP46A1, HSD17B11 | DPP4 3144/4885DPP8 1018/4885DPP9 3152/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | DPP4 4653/4885DPP8 3900/4885DPP9 4621/4885 |
| US-20180155322-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | DPP4 4653/4885DPP8 3900/4885DPP9 4621/4885 |
| US-10647698-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | DPP4 4653/4885DPP8 3900/4885DPP9 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.